Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1967 2
1968 4
1969 2
1970 3
1971 2
1973 4
1974 4
1975 4
1976 3
1977 2
1978 1
1979 3
1980 6
1981 2
1982 3
1983 4
1984 6
1985 9
1986 6
1987 4
1988 9
1989 11
1990 6
1991 10
1992 9
1993 5
1994 15
1995 16
1996 18
1997 17
1998 16
1999 19
2000 17
2001 17
2002 35
2003 40
2004 31
2005 35
2006 38
2007 43
2008 46
2009 42
2010 52
2011 52
2012 63
2013 66
2014 62
2015 46
2016 55
2017 48
2018 52
2019 53
2020 46
2021 18
Text availability
Article attribute
Article type
Publication date

Search Results

1,054 results
Results by year
Filters applied: . Clear all
Page 1
N-Acetylcysteine in the Treatment of Excoriation Disorder: A Randomized Clinical Trial.
Grant JE, Chamberlain SR, Redden SA, Leppink EW, Odlaug BL, Kim SW. Grant JE, et al. JAMA Psychiatry. 2016 May 1;73(5):490-6. doi: 10.1001/jamapsychiatry.2016.0060. JAMA Psychiatry. 2016. PMID: 27007062 Clinical Trial.
Data analysis was performed from July 16 to September 9, 2015. INTERVENTIONS: N-acetylcysteine (dosing range, 1200-3000 mg/d) or placebo was administered for 12 weeks. ...Compared with placebo, N-acetylcysteine treatment was associated with significant improvements …
Data analysis was performed from July 16 to September 9, 2015. INTERVENTIONS: N-acetylcysteine (dosing range, 1200-3000 mg/d) or plac …
Role of N-acetylcysteine treatment in non-acetaminophen-induced acute liver failure: A prospective study.
Nabi T, Nabi S, Rafiq N, Shah A. Nabi T, et al. Saudi J Gastroenterol. 2017 May-Jun;23(3):169-175. doi: 10.4103/1319-3767.207711. Saudi J Gastroenterol. 2017. PMID: 28611340 Free PMC article. Clinical Trial.
To date, there is no established treatment for non-acetaminophen-induced acute liver failure (NAI-ALF) other than liver transplantation, and little is known about the use of N-acetylcysteine (NAC) in NAI-ALF. A randomized case control study was conducted with the aim to de …
To date, there is no established treatment for non-acetaminophen-induced acute liver failure (NAI-ALF) other than liver transplantation, and …
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Idiopathic Pulmonary Fibrosis Clinical Research Network, et al. N Engl J Med. 2012 May 24;366(21):1968-77. doi: 10.1056/NEJMoa1113354. Epub 2012 May 20. N Engl J Med. 2012. PMID: 22607134 Free PMC article. Clinical Trial.
BACKGROUND: A combination of prednisone, azathioprine, and N-acetylcysteine (NAC) has been widely used as a treatment for idiopathic pulmonary fibrosis. ...
BACKGROUND: A combination of prednisone, azathioprine, and N-acetylcysteine (NAC) has been widely used as a treatment for idiopathic …
N-acetylcysteine as an adjunctive treatment for smoking cessation: a randomized clinical trial.
Machado RCBR, Vargas HO, Baracat MM, Urbano MR, Verri WA Jr, Porcu M, Nunes SOV. Machado RCBR, et al. Braz J Psychiatry. 2020 Sep-Oct;42(5):519-526. doi: 10.1590/1516-4446-2019-0753. Braz J Psychiatry. 2020. PMID: 32725102 Free PMC article. Clinical Trial.

RESULTS: First-line treatment for smoking cessation plus adjunctive N-acetylcysteine or placebo significantly reduced COexh (p < 0.01). In the N-acetylcysteine group, no significant changes were found in nicotine withdrawal symptoms, depressive and anxiety sympto

RESULTS: First-line treatment for smoking cessation plus adjunctive N-acetylcysteine or placebo significantly reduced COexh (p < 0

Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis.
Nguyen-Khac E, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, Tramier B, Dewaele F, Ghrib S, Rudler M, Carbonell N, Tossou H, Bental A, Bernard-Chabert B, Dupas JL; AAH-NAC Study Group. Nguyen-Khac E, et al. N Engl J Med. 2011 Nov 10;365(19):1781-9. doi: 10.1056/NEJMoa1101214. N Engl J Med. 2011. PMID: 22070475 Free article. Clinical Trial.
We investigated whether combination therapy with glucocorticoids plus N-acetylcysteine would improve survival. METHODS: We randomly assigned 174 patients to receive prednisolone plus N-acetylcysteine (85 patients) or only prednisolone (89 patients). ...RESULTS: Mort …
We investigated whether combination therapy with glucocorticoids plus N-acetylcysteine would improve survival. METHODS: We randomly a …
Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19).
de Alencar JCG, Moreira CL, Müller AD, Chaves CE, Fukuhara MA, da Silva EA, Miyamoto MFS, Pinto VB, Bueno CG, Lazar Neto F, Gomez Gomez LM, Menezes MCS, Marchini JFM, Marino LO, Brandão Neto RA, Souza HP; COVID Register Group. de Alencar JCG, et al. Clin Infect Dis. 2021 Jun 1;72(11):e736-e741. doi: 10.1093/cid/ciaa1443. Clin Infect Dis. 2021. PMID: 32964918 Free PMC article. Clinical Trial.
BACKGROUND: A local increase in angiotensin 2 after inactivation of angiotensin-converting enzyme 2 by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may induce a redox imbalance in alveolar epithelium cells, causing apoptosis, increased inflammation and, consequent …
BACKGROUND: A local increase in angiotensin 2 after inactivation of angiotensin-converting enzyme 2 by severe acute respiratory syndrome cor …
Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder.
Tomko RL, Baker NL, Hood CO, Gilmore AK, McClure EA, Squeglia LM, McRae-Clark AL, Sonne SC, Gray KM. Tomko RL, et al. Psychopharmacology (Berl). 2020 Feb;237(2):479-490. doi: 10.1007/s00213-019-05384-z. Epub 2019 Nov 11. Psychopharmacology (Berl). 2020. PMID: 31712969 Free PMC article. Clinical Trial.
OBJECTIVES: The goal of this secondary analysis was to examine whether N-acetylcysteine (NAC) reduced depressive symptoms among adults (age 18-50) with CUD (N = 302) and whether the effect of NAC on cannabis cessation varied as a result of baseline levels of depression. .. …
OBJECTIVES: The goal of this secondary analysis was to examine whether N-acetylcysteine (NAC) reduced depressive symptoms among adult …
A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo.
Berk M, Turner A, Malhi GS, Ng CH, Cotton SM, Dodd S, Samuni Y, Tanious M, McAulay C, Dowling N, Sarris J, Owen L, Waterdrinker A, Smith D, Dean OM. Berk M, et al. BMC Med. 2019 Jan 25;17(1):18. doi: 10.1186/s12916-019-1257-1. BMC Med. 2019. PMID: 30678686 Free PMC article. Clinical Trial.
We aimed to examine efficacy of two add-on treatments in bipolar depression: N-acetylcysteine (NAC) and NAC with a combination of nutraceutical agents that may increase mitochondrial biogenesis. ...
We aimed to examine efficacy of two add-on treatments in bipolar depression: N-acetylcysteine (NAC) and NAC with a combination of nut …
N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study.
Li F, Welling MC, Johnson JA, Coughlin C, Mulqueen J, Jakubovski E, Coury S, Landeros-Weisenberger A, Bloch MH. Li F, et al. J Child Adolesc Psychopharmacol. 2020 Feb;30(1):32-37. doi: 10.1089/cap.2019.0041. Epub 2019 Dec 3. J Child Adolesc Psychopharmacol. 2020. PMID: 31800306 Free PMC article. Clinical Trial.
Glutamate dysfunction may contribute to the development of OCD. N-acetylcysteine (NAC), a glutamate modulating drug, has shown to be a promising agent in adults with OCD. ...
Glutamate dysfunction may contribute to the development of OCD. N-acetylcysteine (NAC), a glutamate modulating drug, has shown to be …
1,054 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page